Solan Headlines

Diabetic Peripheral Neuropathy Pipeline

The Diabetic Peripheral Neuropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Diabetic Peripheral Neuropathy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy Market.

Some of the key takeaways from the Diabetic Peripheral Neuropathy Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Diabetic Peripheral Neuropathy treatment therapies with a considerable amount of success over the years. 

• Diabetic Peripheral Neuropathy companies working in the treatment market are Praetego, Mitsubishi Tanabe Pharma, Regenacy Pharmaceuticals, WinSanTor, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, and others, are developing therapies for the Diabetic Peripheral Neuropathy treatment 

• Emerging Diabetic Peripheral Neuropathy therapies in the different phases of clinical trials are- PTG-630, MT-8554, Ricolinostat, WST 057, Engensis, VM202, LX9211, GRC 17536, Ricolinostat, CBD, VX-548, LY3857210, and others are expected to have a significant impact on the Diabetic Peripheral Neuropathy market in the coming years.   

• In March 2024, Researchers at UT Southwestern Medical Center discovered that surgical nerve decompression, commonly used for conditions like carpal tunnel syndrome and sciatica, may also help alleviate pain in diabetic neuropathy patients.

• In December 2023, Vertex Pharmaceuticals announced that VX-548 achieved the primary endpoint in a Phase II dose-ranging trial for patients with painful diabetic peripheral neuropathy (DPN). According to the company, all dosage groups treated with VX-548 demonstrated a statistically significant and clinically meaningful reduction in the primary endpoint, which was the change from baseline on the Numeric Pain Rating Scale (NPRS) at week 12 in the trial (NCT05660538).

Diabetic Peripheral Neuropathy Overview

Diabetic Peripheral Neuropathy (DPN) is a type of nerve damage that can occur in individuals with diabetes. It affects the peripheral nerves, which are the nerves outside the brain and spinal cord. DPN commonly affects the nerves in the legs and feet, causing symptoms such as pain, tingling, numbness, and weakness. 

Get a Free Sample PDF Report to know more about Diabetic Peripheral Neuropathy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-pipeline-insight

Emerging Diabetic Peripheral Neuropathy Drugs Under Different Phases of Clinical Development Include:

• PTG-630: Praetego

• MT-8554: Mitsubishi Tanabe Pharma

• Ricolinostat: Regenacy Pharmaceuticals

• WST 057: WinSanTor

• Engensis: Helixmith

• VM202: Helixmith

• LX9211: Lexicon Pharmaceuticals

• GRC 17536: Glenmark Pharmaceuticals

• Ricolinostat: Regenacy Pharmaceuticals

• CBD: Pure Green

• VX-548: Vertex Pharmaceuticals Incorporated

• LY3857210: Eli Lilly and Company

Diabetic Peripheral Neuropathy Route of Administration

Diabetic Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Infusion

• Intradermal

• Intramuscular

• Intranasal

• Intravaginal

• Oral

• Parenteral

• Subcutaneous

• Topical.

• Molecule Type

Diabetic Peripheral Neuropathy Molecule Type

Diabetic Peripheral Neuropathy Products have been categorized under various Molecule types, such as

• Gene therapies

• Small molecule

• Product Type

Diabetic Peripheral Neuropathy Pipeline Therapeutics Assessment

• Diabetic Peripheral Neuropathy Assessment by Product Type

• Diabetic Peripheral Neuropathy By Stage and Product Type

• Diabetic Peripheral Neuropathy Assessment by Route of Administration

• Diabetic Peripheral Neuropathy By Stage and Route of Administration

• Diabetic Peripheral Neuropathy Assessment by Molecule Type

• Diabetic Peripheral Neuropathy by Stage and Molecule Type

DelveInsight’s Diabetic Peripheral Neuropathy Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Diabetic Peripheral Neuropathy product details are provided in the report. Download the Diabetic Peripheral Neuropathy pipeline report to learn more about the emerging Diabetic Peripheral Neuropathy therapies

Some of the key companies in the Diabetic Peripheral Neuropathy Therapeutics Market include:

Key companies developing therapies for Diabetic Peripheral Neuropathy are – Eli Lilly and Company, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Aptinyx, Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Daiichi Sankyo, Inc., Avazzia, Inc., and others.

Diabetic Peripheral Neuropathy Pipeline Analysis:

The Diabetic Peripheral Neuropathy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Peripheral Neuropathy with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Peripheral Neuropathy Treatment.

• Diabetic Peripheral Neuropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Diabetic Peripheral Neuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Peripheral Neuropathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Peripheral Neuropathy drugs and therapies

Diabetic Peripheral Neuropathy Pipeline Market Drivers

• Increasing prevalence of diabetes cases and growing aging population, rising R&D activities for drug discovery and development are some of the important factors that are fueling the Diabetic Peripheral Neuropathy Market.

Diabetic Peripheral Neuropathy Pipeline Market Barriers

• However, high failure rate in clinical trials, stringent regulatory requirements, and longer approval time for drugs and other factors are creating obstacles in the Diabetic Peripheral Neuropathy Market growth.

Scope of Diabetic Peripheral Neuropathy Pipeline Drug Insight    

• Coverage: Global

• Key Diabetic Peripheral Neuropathy Companies: Praetego, Mitsubishi Tanabe Pharma, Regenacy Pharmaceuticals, WinSanTor, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, and others

• Key Diabetic Peripheral Neuropathy Therapies: PTG-630, MT-8554, Ricolinostat, WST 057, Engensis, VM202, LX9211, GRC 17536, Ricolinostat, CBD, VX-548, LY3857210, and others

• Diabetic Peripheral Neuropathy Therapeutic Assessment: Diabetic Peripheral Neuropathy current marketed and Diabetic Peripheral Neuropathy emerging therapies

• Diabetic Peripheral Neuropathy Market Dynamics: Diabetic Peripheral Neuropathy market drivers and Diabetic Peripheral Neuropathy market barriers 

Request for Sample PDF Report for Diabetic Peripheral Neuropathy Pipeline Assessment and clinical trials

Table of Contents

1. Diabetic Peripheral Neuropathy Report Introduction

2. Diabetic Peripheral Neuropathy Executive Summary

3. Diabetic Peripheral Neuropathy Overview

4. Diabetic Peripheral Neuropathy- Analytical Perspective In-depth Commercial Assessment

5. Diabetic Peripheral Neuropathy Pipeline Therapeutics

6. Diabetic Peripheral Neuropathy Late Stage Products (Phase II/III)

7. Diabetic Peripheral Neuropathy Mid Stage Products (Phase II)

8. Diabetic Peripheral Neuropathy Early Stage Products (Phase I)

9. Diabetic Peripheral Neuropathy Preclinical Stage Products

10. Diabetic Peripheral Neuropathy Therapeutics Assessment

11. Diabetic Peripheral Neuropathy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diabetic Peripheral Neuropathy Key Companies

14. Diabetic Peripheral Neuropathy Key Products

15. Diabetic Peripheral Neuropathy Unmet Needs

16 . Diabetic Peripheral Neuropathy Market Drivers and Barriers

17. Diabetic Peripheral Neuropathy Future Perspectives and Conclusion

18. Diabetic Peripheral Neuropathy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services